0001209191-20-046502.txt : 20200812 0001209191-20-046502.hdr.sgml : 20200812 20200812213651 ACCESSION NUMBER: 0001209191-20-046502 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200812 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kowalski Mark CENTRAL INDEX KEY: 0001628357 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 201096982 MAIL ADDRESS: STREET 1: C/O ARBUTUS BIOPHARMA CORP. STREET 2: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ? 885 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 BUSINESS PHONE: 604-558-6536 MAIL ADDRESS: STREET 1: 2150 ? 885 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-12 0 0001290149 Sierra Oncology, Inc. SRRA 0001628357 Kowalski Mark C/O SIERRA ONCOLOGY, INC. 2150 885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Medical Officer Stock Option (right to buy) 12.15 2020-08-12 4 A 0 24970 0.00 A 2030-08-12 Common Stock 24970 24970 D The option vests as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Mark Kowalski, by Sukhi Jagpal, Attorney-in-Fact 2020-08-12